The prediction study of the effect of antibody therapy using antibody dependent cell-mediated cytotoxicity with blood sample
Not Applicable
- Conditions
- malignant solid tumor
- Registration Number
- JPRN-UMIN000002320
- Lead Sponsor
- national cancer center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
* patients determined ineligible for this study by the researcher
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ADCC in antibody therapy for malignant solid tumors?
How does ADCC-based antibody therapy compare to standard-of-care treatments for solid tumors?
Which biomarkers are associated with response prediction in ADCC studies for cancer therapy?
What are the potential adverse events linked to ADCC mechanisms in antibody therapies for tumors?
Are there combination approaches or competitor drugs enhancing ADCC effects in solid tumor treatment?